Project Grant R21AA031033

Award Date 5/1/24
Completion Date 4/30/26
Dollars Obligated $622K
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
This $235,750 Project Grant award, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to leverage existing human serum samples from longitudinal studies to characterize the effects of alcohol use disorder (AUD) and various treatments on extracellular vesicles (EVs) and their protein/lipid profiles. The goal is to assess the utility of EV-based serum diagnostics for detecting and monitoring alcohol-related white...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) grant program, supports research to investigate the effects of chronic alcohol exposure on the biogenesis, distribution, and RNA content of astrocyte-derived exosomes. The $187,031 award, effective September 1, 2024 through August 31, 2026, will enable the University of California, Los Angeles (UCLA) to develop an in vivo model for tracking...
This $119,600 project grant, awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to investigate the cooperative mechanisms by which aging and alcohol consumption contribute to the development of alcohol-associated liver disease (ALD). The principal investigator at the University of Kansas Medical Center Research Institute, Inc. will focus on understanding how autophagy, endoplasmic reticulum stress, and lysosomal...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, supports research to examine the role of non-parenchymal cells in driving the key features of alcohol-associated hepatitis (AAH) in a fully humanized mouse liver model. The $688,199 award, effective June 1, 2025 through February 28, 2030, will enable researchers at Yale University to investigate specific ligand-receptor...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) totaling $523,477 focuses on studying alcohol-associated liver disease (ALD) and its interaction with the rs738409 variant in PNPLA3 using a human induced pluripotent stem cell (hiPSC)-derived liver culture model. The awardee, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will investigate key mechanisms underlying ALD...
This $148,449 Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program supports research into how alcohol metabolism and HIV infection contribute to multi-organ health problems. The objectives of this grant are to investigate how alcohol consumption by people living with HIV (PLWH) leads to the release of extracellular vesicles (EVs) from infected lung cells, which then promote inflammation and...
This federal Project Grant award, valued at $442,898 and funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), will support research to define the contributions of the MIF-CD74 signaling pathway in alcohol-associated liver disease (ALD). The University of Texas Health Science Center at Houston, the awardee, will conduct this research over a 5-year period from September 1, 2024 to July 31, 2029. The key objectives are to: 1)...
The University of California, San Diego (UCSD) was awarded a $414,750 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to investigate the role of intestinal gp130 signaling in preventing alcohol-associated liver disease. The proposed research aims to define the gp130-STAT3-Reg3 signaling axis involved in protecting against ethanol-induced liver disease and assess the potential of a novel engineered gp130...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $1,158,934 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The grant, titled "Mechanisms of Mitochondrial Dynamics, Quality Control and mtDNA-Mediated Inflammation in Alcohol-Associated Liver Disease", aims to investigate the role of mitochondrial dysfunction and inflammation in the development...

A MOLECULAR MECHANISM OF EXTRACELLULAR VESICLE PRODUCTION BY ALCOHOLIC LIVERS ANDTHE FUNCTIONAL IMPACT - CHRONIC EXCESSIVE ALCOHOL DRINKING CAN LEAD TO SERIOUS LIVER INJURY. ALCOHOLIC LIVER DISEASE OR ALCOHOL-ASSOCIATED/RELATED LIVER DISEASE (ALD) IS CHARACTERIZED BY STEATOSIS, INFLAMMATION, AND FIBROSIS, WHICH CAN LEAD TO CIRRHOSIS, CANCER AND MULTIPLE COMPLICATIONS. WHILE SIGNIFICANT PROGRESS HAS BEEN MADE, MUCH HAS YET TO BE LEARNT ABOUT THE PATHOGENESIS OF ALCOHOL-INDUCED LIVER INJURY TO DEVELOP EFFECTIVE THERAPY AND DIAGNOSIS. EXTRACELLULAR VESICLES (EVS) ARE INTRACELLULAR VESICLES RELEASED BY CELLS INTO THE EXTRACELLULAR SPACE IN RESPONSE TO VARIOUS PHYSIOLOGICAL AND PATHOLOGICAL SIGNALS. INCREASED PRODUCTION OF EVS IN ALD HAS BEEN FOUND TO CONTRIBUTE TO THE PATHOGENESIS OF ALD IN A SIGNIFICANT WAY. BUT THE MECHANISM OF ENHANCED EV PRODUCTION UNDER CHRONIC ALCOHOL EXPOSURE IS NOT KNOWN. ON THE OTHER HAND, AUTOPHAGY IS AN EVOLUTIONARILY CONSERVED PROCESS, AND ITS DISTURBANCE CAN CONTRIBUTE TO ALD WITH THE MOLECULAR PATHWAY UNDEFINED. INTERESTINGLY, WE FIND THAT EVS PRODUCED IN AUTOPHAGY DEFICIENT MICE CARRY THE SAME MOLECULAR SIGNATURES AS THOSE GENERATED BY ALCOHOL-FED MICE. OUR PRELIMINARY FINDINGS SUPPORT A HYPOTHESIS THAT EV PRODUCTION IN ALD CONDITION COULD BE DRIVEN BY A UNIQUE REGULATORY PATHWAY INVOLVING AUTOPHAGY INHIBITION, ACTIVATION OF NRF2 AND UPREGULATION OF SDCBP2 AND THAT THESE MOLECULES CAN HAVE FUNCTIONAL IMPACT ON THE LIVER PATHOLOGIES VIA THE EVS. TO EXAMINE THIS HYPOTHESIS, WE HAVE PROPOSED TWO SPECIFIC AIMS. IN AIM 1, WE WILL DETERMINE THE MECHANISM OF EV PRODUCTION IN A MOUSE MODEL OF ALD. HERE WE WILL EXAMINE HOW AUTOPHAGY DEFICIENCY FOLLOWING CHRONIC ALCOHOL EXPOSURE COULD PROMOTE EVS PRODUCTION. WE WILL EXAMINE THE MOLECULAR LINK FROM NRF2 TO SDCBP2, BOTH OF WHICH ARE ELEVATED IN EXPRESSION IN GENETICALLY MODIFIED AUTOPHAGY DEFICIENT LIVERS AND IN CHRONIC ALCOHOL-FED LIVERS. UNLIKE THE STEADY GENERATION OF EVS IN BASAL CONDITIONS, THIS IS A REGULATED PATHWAY TO ENHANCE EV PRODUCTION IN RESPONSE TO THE PATHOLOGICAL STIMULATION OF ALCOHOL UPTAKE. IN AIM 2, WE WILL DETERMINE THE CONTRIBUTION OF SDCBP2 VIA ENHANCED EV PRODUCTION TO ALCOHOLIC LIVER PATHOGENESIS. WE WILL EXAMINE THE EFFECT ON INFLAMMATION VIA M1 POLARIZATION AND OTHER LIVER PATHOLOGY. THESE STUDIES WILL ELUCIDATE AN IMPORTANT MECHANISM THAT REGULATE EV PRODUCTION IN ALD (A SHORT- TERM GOAL), WHICH WILL SIGNIFICANTLY ADVANCE THE FIELD AS THE IDENTIFICATION OF NEW MOLECULAR TARGETS COULD POTENTIALLY STIMULATE THERAPEUTIC AND DIAGNOSTIC DEVELOPMENT IN FUTURE R01-BASED STUDIES (AN INTERMEDIATE TERM GOAL), LEADING TO IMPROVED MANAGEMENT OF ALD (A LONG-TERM GOAL).

Posted 4/18/24, 12:00 AM